Amgen Gets Priority Review For Prolia

Published: Jul 19, 2010

Pharma Times -- Amgen has received a boost with the news that regulators in the USA have granted a priority review to the company’s recently-approved denosumab, this time for the reduction of skeletal related events in advanced cancer patients.

Back to news